Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026639 | 0.91 | GRM2 (0.47) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2022406 | 0.84 | GAA (0.45) | GRM2ALDH1A1CHRM5 | |
| SCHEMBL2026888 | 0.83 | GRM2 (0.47) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2018587 | 0.83 | GRM2 (0.47) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL1003171 | 0.82 | CHRM5 (0.48) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12442483 | 0.81 | LSS (0.45) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2021638 | 0.81 | GRM2 (0.46) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2029723 | 0.81 | GRM2 (0.56) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2025257 | 0.81 | GRM2 (0.46) | GRM2GRIN2BALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL2022810 | 0.81 | TNIK (0.37) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885GRIN2B 16/4885ALDH1A1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.